Payment overview · 2025
General Payments
$587.94
33 reported records · 16 companies
Healthcare provider profile · identity verified
Danielle Kahanek Duhon, MD
Allopathic & Osteopathic Physicians|Family Medicine · RAYNE, LA · NPI 1508209792
Verified facts
What the public records show
CMS Open Payments records show Danielle Kahanek Duhon, MD received $587.94 in general payments during 2025 across 33 reported records.
ABBVIE INC. accounted for 28.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $169.08 | 28.8% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.73 | 9.5% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $37.68 | 6.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.53 | 6.0% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $32.76 | 5.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.02 | 5.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.02 | 5.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.82 | 5.2% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $26.14 | 4.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.52 | 3.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.98 | 3.7% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.22 | 3.6% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $18.96 | 3.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.21 | 3.1% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.08 | 3.1% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $16.19 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $587.94 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $118.56 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $67.95 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.73 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.88 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $32.76 | 2 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $31.02 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.02 | 2 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $31.02 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.82 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.21 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 201 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
201 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
101 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 650 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 620 | 147 |
| Metformin Hcl Er | Metformin Hcl | 532 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 517 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 449 | 91 |
| Montelukast Sodium | Montelukast Sodium | 442 | 101 |
| Pioglitazone Hcl | Pioglitazone Hcl | 391 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 369 | 76 |
| Benazepril Hcl | Benazepril Hcl | 305 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 267 | 60 |
| Omeprazole | Omeprazole | 243 | 61 |
| Gabapentin | Gabapentin | 241 | 56 |
| Ramipril | Ramipril | 241 | 53 |
| Ezetimibe | Ezetimibe | 240 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 215 | 45 |
| Trazodone Hcl | Trazodone Hcl | 212 | 44 |
| Losartan Potassium | Losartan Potassium | 210 | 47 |
| Metformin Hcl | Metformin Hcl | 207 | 46 |
| Furosemide | Furosemide | 206 | 46 |
| Lisinopril | Lisinopril | 206 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 201 | 38 |
| Mounjaro | Tirzepatide | 201 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 199 | 75 |
| Simvastatin | Simvastatin | 194 | 35 |
| Buspirone Hcl | Buspirone Hcl | 191 | 37 |
| Potassium Chloride | Potassium Chloride | 191 | 33 |
| Carvedilol | Carvedilol | 189 | 45 |
| Famotidine | Famotidine | 167 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 134 | 102 |
| Tramadol Hcl | Tramadol Hcl | 132 | 38 |
| Prednisone | Prednisone | 120 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 49 |
| Xarelto | Rivaroxaban | 116 | 18 |
| Alendronate Sodium | Alendronate Sodium | 112 | 22 |
| Clonazepam | Clonazepam | 104 | 23 |
| Allopurinol | Allopurinol | 101 | 21 |
| Trulicity | Dulaglutide | 101 | 18 |
| Januvia | Sitagliptin Phosphate | 95 | 11 |
| Spironolactone | Spironolactone | 95 | 19 |
| Cefdinir | Cefdinir | 92 | 78 |
| Felodipine Er | Felodipine | 91 | 20 |
| Glipizide | Glipizide | 91 | 25 |
| Myrbetriq | Mirabegron | 91 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 41 |
| Donepezil Hcl | Donepezil Hcl | 82 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 49 |
| Tradjenta | Linagliptin | 77 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 14 |
| Cephalexin | Cephalexin | 76 | 30 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 71 | 64 |
| Sertraline Hcl | Sertraline Hcl | 71 | 15 |
| Jardiance | Empagliflozin | 67 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 45 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 58 |
| Glimepiride | Glimepiride | 66 | 14 |
| Mirtazapine | Mirtazapine | 65 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 64 | 45 |
| Memantine Hcl | Memantine Hcl | 63 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | suppressed |
| Eliquis | Apixaban | 56 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 52 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 50 | suppressed |
| Glipizide Er | Glipizide | 48 | suppressed |
| Mupirocin | Mupirocin | 47 | 38 |
| Propranolol Hcl | Propranolol Hcl | 47 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 11 |
| Meloxicam | Meloxicam | 46 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 11 |
| Colchicine | Colchicine | 45 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | suppressed |
| Ondansetron Odt | Ondansetron | 42 | 30 |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Valsartan | Valsartan | 41 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 27 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Torsemide | Torsemide | 37 | 12 |
| Azelastine Hcl | Azelastine Hcl | 36 | 14 |
| Finasteride | Finasteride | 36 | suppressed |
| Niacin Er | Niacin | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Multaq | Dronedarone Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Jantoven | Warfarin Sodium | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 20 | 18 |
| Nystatin | Nystatin | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 19 | 15 |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 13 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fluorouracil | Fluorouracil | 11 | suppressed |
| Forteo | Teriparatide | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $587.94 · 33 records | ABBVIE INC. | Azstarys, Cologuard Collection Kit, DUROLANE, Dexcom G6 Transmitter, IBSRELA, JARDIANCE, Jornay PM, MOUNJARO, NEXLETOL, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REXULTI, TRUMENBA, TZIELD, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error